THE JOCKEY CLUB THOROUGHBRED SAFETY COMMITTEE RECOMMENDATIONS AUGUST 22, 2010

Recommendation: Drug Testing & Laboratory Standards

The Racing Medication and Testing Consortium's (RMTC) Drug Testing Initiative is a major step forward in the reorganization and improvement of drug testing in the United States. The development of an equine drug testing code of standards for laboratory accreditation by the RMTC and consolidation of the current industry quality assurance and proficiency programs into a single, independently monitored program will result in comprehensive reform and improvement to U.S. equine drug testing. The Thoroughbred Safety Committee calls for

"The adoption of the RMTC Equine Drug Testing Standards into the Association of Racing Commissioners International Model Rule book and the participation and adoption of the standards by all United States racing authorities and their associated testing laboratories."

The Thoroughbred Safety Committee encourages all laboratories that perform drug testing for horse racing to demonstrate their commitment to RMTC accreditation by executing letters of intent to complete the accreditation process. The committee also applauds the efforts of the following drug testing laboratories that have signed letters of intent, as of August 22, 2010, to complete the accreditation process no later than December 31, 2011.

- Dalare Associates, Philadelphia, PA
- HFL Sports Science, Lexington, KY
- Morrisville State College, Morrisville, NY
- The Ken Maddy Racing Laboratory at the University of California Davis, Davis, CA
- Pennsylvania Equine Toxicology and Research Laboratory, West Chester, PA

In addition to the Equine Drug Testing Standards included in the accreditation of each lab, the following is also included in the accreditation process:

- Develop a uniform request for proposal from state racing commissions for drug testing laboratory services that requires adherence to the above standards and requires compliance with international drug testing accreditation specifications (ISO/IEC 17025)
- Participation in a frozen sample program for a minimum of five years for future analysis as new drug tests are developed
- o On-going participation in a blind quality assurance program